Jardiance Under Review for CKD; Frailty in Obesity; DIY Semaglutide?

(MedPage Today) -- The FDA is reviewing a potential new indication for empagliflozin (Jardiance) for risk reduction of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD) based on the EMPA-KIDNEY phase...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news